Ionis Pharmaceuticals (IONS)
NASDAQ: IONS · Biotechnology · Carlsbad, CA
Our rating: Neutral
Call changed from Positive to Neutral at $28.01, moderate conviction, November 16, 2026.
Breaks if: For Neutral to become Positive: next full fiscal year revenue reaches at least $1.2B (roughly 27% growth from the reported $944M) while FCF burn narrows to below $200M — both conditions required, as growth without improving cash economics does not change the thesis. For Neutral to become Cautious: year-over-year revenue growth decelerates below 10% in the next reported annual figures, or FCF burn widens beyond $450M in the next full fiscal year.
Key figures
| Market value | $4.4B |
|---|---|
| Revenue, last 12 months | $960M |
| Net income, last 12 months | −$547M |
| Free cash flow, last 12 months | −$616M |
| Price to earnings | n/a |
| Free cash flow yield | −13.9% |
| Dividend yield | 0.0% |
| Operating margin | −58.8% |
| Return on equity | −108.1% |
| Beta to the S&P 500 | 0.63 |
| Volatility, annualized | 49.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $243M | 54.9% | $-0.66 | −$192M |
| June 30, 2026 | $268M | −40.7% | $-0.69 | $549M |
| March 31, 2026 | $246M | 87.0% | $-0.56 | −$815M |
| December 31, 2025 | $203M | −10.3% | $-1.41 | −$159M |
| September 30, 2025 | $157M | 17.1% | $-0.80 | −$137M |
| June 30, 2025 | $452M | 100.7% | $0.70 | $139M |
| March 31, 2025 | $132M | 10.1% | $-0.93 | −$163M |
| December 31, 2024 | $227M | −30.2% | $-0.66 | −$142M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.25B: Claude 55%, Gemini 70%, Mistral 62%
- Diluted earnings per share are above zero: Claude 12%, Gemini 12%, Mistral 20%
- Free cash flow for the quarter is above zero: Claude 30%, Gemini 35%, Mistral 30%
24 ledger entries and 34 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.